Tricuspid atresia medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 7: | Line 7: | ||
*The mainstay of therapy for the cyanotic neonate with severe[[ pulmonary stenosis]] and small sized [[VSD]] is using[[ prostaglandin E1]] (PGE1) for keeping patency of [[ductus arteriosis]]. | *The mainstay of therapy for the cyanotic neonate with severe[[ pulmonary stenosis]] and small-sized [[VSD]] is using[[ prostaglandin E1]] (PGE1) for keeping patency of [[ductus arteriosis]]. | ||
*The mainstay of therapy for [[heart failure]] symptoms is using [[diuretic]] for reduction of [[congestion ]]and then starting [[ ACEI]]. | *The mainstay of therapy for [[heart failure]] symptoms is using [[diuretic]] for reduction of [[congestion]] and then starting [[ ACEI]]. | ||
==References== | ==References== | ||
Revision as of 16:16, 24 August 2020
|
Tricuspid atresia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Special Scenarios |
|
Case Studies |
|
Tricuspid atresia medical therapy On the Web |
|
American Roentgen Ray Society Images of Tricuspid atresia medical therapy |
|
Risk calculators and risk factors for Tricuspid atresia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Sara Zand, M.D.[2]Keri Shafer, M.D. [3] Priyamvada Singh, MBBS [4]; Assistant Editor-In-Chief: Kristin Feeney, B.S. [5]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Medical Therapy
- The mainstay of therapy for the cyanotic neonate with severepulmonary stenosis and small-sized VSD is usingprostaglandin E1 (PGE1) for keeping patency of ductus arteriosis.
- The mainstay of therapy for heart failure symptoms is using diuretic for reduction of congestion and then starting ACEI.